Two phase 3 trials of dronedarone, a novel class III antiarrhythmic agent currently in development worldwide, have demonstrated that the drug is safe and effective for the maintenance of normal sinus ...
Vancouver, BC - A new, acute-use intravenous antiarrhythmic agent has been shown to be efficacious in the treatment of atrial fibrillation (AF). A recent study with the compound, known as RSD1235 ...
HBI-3000 Aims to Fill Critical Gaps in Atrial Fibrillation Care; Key Data to be Presented at the American Heart Association Annual Meeting SAN DIEGO, Nov. 14, 2024 /PRNewswire/ -- HUYABIO ...
Atrial fibrillation (AF) is the most common arrhythmia that requires medical attention. Patients with significant symptoms related to AF may benefit from efforts to restore and maintain normal sinus ...
Please provide your email address to receive an email when new articles are posted on . Dronedarone is a noniodinated benzofuran derivative of amiodarone that was specifically designed to improve the ...
There are limited data comparing radiofrequency catheter ablation with antiarrhythmic drug therapy as first-line treatment in patients with paroxysmal atrial fibrillation. We randomly assigned 294 ...
heart ecg arrhythmia The FDA has approved the Prior Approval Supplement for Bretylium Tosylate Injection, allowing ANI Pharmaceuticals to market the once discontinued antiarrhythmic agent. The Food ...
HUYABIO Validates Protective Mechanism for Antiarrhythmic Drug HBI-3000 in AF Patients, Paving the Way for a New Era in Atrial Fibrillation Treatment PR Newswire SAN DIEGO, Nov. 14, 2024 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback